The Molecular Mechanism of Platelet Activation in Inflammation

Histones, typically confined to the nucleus for DNA packaging, exhibit a critical shift in function when released extracellularly, acting as damage-associated molecular patterns (DAMPs) that contribute to inflammation and thrombosis. This study investigates the role of extracellular histones in platelet activation, exploring their pro-thrombotic effects and the molecular pathways involved. Using flow cytometry, platelet activation was quantified through P-selectin (CD62P) expression, revealing a dose-dependent response, with 91.6% activation at 10 µg/ml histone concentration compared to a 2.4% baseline.

The findings in this study suggest that histones interact with platelet membranes and, due to their positive charge, disrupt membrane potential and trigger the degranulation process. Consequently, platelet release agonists that affect multiple receptor pathways, possibly including adenosine diphosphate (ADP), thromboxane A2 and toll-like receptors (TLRs), to drive platelet activation. This highlights the potential role of extracellular histones in thrombo-inflammatory diseases, including sepsis, trauma, and autoimmune conditions such as ANCA-associated vasculitis (AAV).

To mitigate histone-induced platelet activation, this study examined the efficacy of potential inhibitors, heparin, heparan sulfate (HS), aspirin, and cangrelor. Heparin and HS effectively neutralised histone activity in a dose-dependent manner, with heparin demonstrating nearly complete inhibition at 12.5 U/ml, while HS at 100 µg/ml entirely suppressed activation. Additionally, the antiplatelet agents aspirin and cangrelor significantly reduced histone mediated activation by targeting thromboxane A2 and P2Y12 receptor-mediated pathways, respectively. These findings suggest that histones directly disrupt the platelet membranes, which is followed by the release of agonists that engage multiple receptors on the platelet surface. This necessitates multi-pathway inhibition strategies to effectively counteract histone effects.

This study provides key insights into histone-mediated platelet activation and its inhibition, reinforcing the potential therapeutic benefits of anticoagulant and antiplatelet drugs in preventing excessive thrombosis in conditions associated with elevated extracellular histones. The research highlights novel therapeutic approaches for thrombo-inflammatory diseases such as sepsis, trauma, and AAV by identifying heparin, HS, aspirin, and cangrelor as effective inhibitors. Furthermore, these findings emphasise the need for in vivo studies to validate proposed therapeutic approaches and explore their clinical applications. The integration of molecular insights with translational medicine underscores the importance of targeted, multi-faceted strategies in mitigating histone-induced thrombosis and improving patient outcomes.